Ascentage Pharma Group International (HKG:6855)
50.90
+1.40 (2.83%)
At close: Jan 23, 2026
HKG:6855 Revenue
Ascentage Pharma Group International had revenue of 116.85M CNY in the half year ending June 30, 2025, a decrease of -71.63%. This brings the company's revenue in the last twelve months to 390.60M, down -56.75% year-over-year. In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M with 341.77% growth.
Revenue (ttm)
390.60M CNY
Revenue Growth
-56.75%
P/S Ratio
43.77
Revenue / Employee
688.89K CNY
Employees
567
Market Cap
18.73B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genscript Biotech | 6.50B |
| Zai Lab | 3.44B |
| Duality Biotherapeutics | 2.38B |
| InnoCare Pharma | 1.56B |
| Biocytogen Pharmaceuticals (Beijing) | 1.30B |
| Keymed Biosciences | 955.73M |
| Everest Medicines | 932.82M |
| Mirxes Holding Company | 166.32M |
Ascentage Pharma Group International News
- 5 days ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 10 days ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga
- 7 weeks ago - Ascentage Gets Regulatory Clearance In The US And Europe To Conduct POLARIS-1 Trial - Nasdaq
- 7 weeks ago - Ascentage Pharma To Launch Global Phase III Study Of Olverembatinib In Ph+ ALL - Nasdaq
- 2 months ago - This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
- 2 months ago - Ascentage Pharma Group (AAPG): Piper Sandler Initiates Coverage with Overweight Rating | AAPG ... - GuruFocus
- 5 months ago - Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha